|
[1] FENG G, HAN HJ, QI X, et al. Establishment of a noninvasive diagnosis quation for nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2018, 34 (6) :1264-1267. (in Chinese) 冯巩, 韩海静, 齐雪, 等.非酒精性脂肪性肝病无创性诊断方程的构建[J].临床肝胆病杂志, 2018, 34 (6) :1264-1267.
|
|
[2] BARGIGGIA S, MACONI G, ELLI M, et al. Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease:Study of 511 subjects at a single center[J]. J Clin Gastroenterol, 2003, 36 (5) :417-420.
|
|
[3] ROCCHI A, BENCHIMOL EI, BERNSTEIN CN, et al. Inflammatory bowel disease:A Canadian burden of illness review[J]. Can J Gastroenterol, 2012, 26 (11) :811-817.
|
|
[4] AHMED A, WONG RJ, HARRISON SA. Nonalcoholic fatty liver disease review:Diagnosis, treatment, and outcomes[J]. Clin Gastroenterol Hepatol, 2015, 13 (12) :2062-2070.
|
|
[5] CAPPELLO M, RANDAZZO C, BRAVATI, et al. Liver function test abnormalities in patients with inflammatory bowel diseases:A hospital-based survey[J]. Clin Med Insights Gastroenterol, 2014, 7:25-31.
|
|
[6] THIN L WY, LAWRANCE IC, SPILSBURY K, et al. Detection of liver injury in IBD using transient elastography[J]. J Crohns Colitis, 2014, 8 (7) :671-677.
|
|
[7] VERMA S, JENSEN D, HART J, et al. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD) [J]. Liver Int, 2013, 33 (9) :1398-1405.
|
|
[8] CHANDRASHEKARAN V, SETH RK, DATTAROY D, et al.HMGB1-RAGE pathway drives peroxynitrite signaling-induced IBD-like inflammation in murine nonalcoholic fatty liver disease[J]. Redox Biol, 2017, 13:8-19.
|
|
[9] BESSISSOW T, LE NH, ROLLET K, et al. Incidence and predictors of nonalcoholic fatty liver disease by serum biomarkers in patients with inflammatory bowel disease[J]. Inflamm Bowel Dis, 2016, 22 (8) :1937-1944.
|
|
[10] SOURIANARAYANANE A, GARG G, SMITH TH, et al. Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease[J]. J Crohns Colitis, 2013, 7 (8) :e279-e285.
|
|
[11] BOSCH DUSTIN E, YEH MATTHEW M. Primary sclerosing cholangitis is protective against nonalcoholic fatty liver disease in inflammatory bowel disease[J]. Hum Pathol, 2017, 69:55-62.
|
|
[12] CHAO CY, BATTAT R, AL KHOURY A, et al. Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease:A review article[J]. World J Gastroenterol, 2016, 22 (34) :7727-7734.
|
|
[13] NIRIELLA MA, DE SILVA ST, KASTURIRATNA A, et al. Lean non-alcoholic fatty liver disease (Lean-NAFLD) :Characteristics and risk factors from a community cohort follow up study[C]//Sri Lanka Medical Association, 2016.
|
|
[14] WIEST R, ALBILLOS A, TRAUNER M, et al. Targeting the gutliver axis in liver disease[J]. J Hepatol, 2017, 67 (5) :1084-1103.
|
|
[15] TILG H, CANI PD, MAYER EA. Gut microbiome and liver diseases[J]. Gut, 2016, 65 (12) :2035.
|
|
[16] BOURSIER J, MUELLER O, BARRET M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota[J]. Hepatology, 2016, 63 (3) :764-775.
|
|
[17] LLOPIS M, CASSARD AM, WRZOSEK L, et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease[J]. Gut, 2016, 65 (5) :830-839.
|
|
[18] SABINO J, VIEIRA-SILVA S, MACHIELS K, et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD[J]. Gut, 2016, 65 (10) :1681-1690.
|
|
[19] LACHAR J, BAJAJ JS. Changes in the microbiome in cirrhosis and relationship to complications:Hepatic encephalopathy, spontaneous bacterial peritonitis, and sepsis[J]. Semin Liver Dis, 2016, 36 (4) :327-330.
|
|
[20] BAJAJ JS, FAGAN A, SIKAROODI M, et al. Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis[J]. Liver Transpl, 2017, 23 (7) :907-914.
|
|
[21] CANI PD, AMAR J, IGLESIAS MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance[J]. Diabetes, 2007, 56 (7) :1761-1772.
|
|
[22] SPADONI L, ZAGATO E, BERTOCCHI A, et al. A gut-vascular barrier controls the systemic dissemination of bacteria[J]. Science, 2015, 350 (6262) :830-834.
|
|
[23] YILMAZ Y. Review article:Is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?[J]. Aliment Pharmacol Ther, 2012, 36 (9) :815-823.
|
|
[24] SMYTHIES LE, WAITES KB, LINDSEY JR, et al. Helicobacter pylori-induced mucosal inflammation is Th1 mediated and exacerbated in IL-4, but not IFN-gamma, gene-deficient mice[J]. J Immunol, 2000, 165 (2) :1022-1029.
|
|
[25] RESTELLINI S, CHAZOUILLRES O, FROSSARD JL. Hepatic manifestations of inflammatory bowel diseases[J]. Liver Int, 2017, 37 (4) :475-489.
|
|
[26] GANZETTI G, CAMPANATI A, OFFIDANI A. Non-alcoholic fatty liver disease and psoriasis:So far, so near[J]. World J Hepatol, 2015, 7 (3) :315-326.
|
|
[27] LU C. Study on the influence of inflammatory bowel disease on hepatic fat changes[D]. Zhejiang:Zhejiang Univ, 2016. (in Chinese) 陆超.炎症性肠病对肝脏脂变影响的研究[D].浙江:浙江大学, 2016.
|
|
[28] MIKOLASEVIC I, LUKENDA V, RACKI S, et al. Nonalcoholic fatty liver disease (NAFLD) -a new factor that interplays between inflammation, malnutrition, and atherosclerosis in elderly hemodialysis patients[J]. Clin Interv Aging, 2014, 9:1295-1303.
|
|
[29] SANADA Y, URAHASHI T, WAKIYA T, et al. Non-alcoholic steatohepatitis caused by malnutrition after pediatric liver transplantation[J]. Pediatr Int, 2011, 53 (6) :1077-1081.
|
|
[30] FAN JG, LI F, CAI XB, et al. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders[J]. J Gastroenterol Hepatol, 2007, 22 (7) :1086-1091.
|
|
[31] ANGELICO M, DELLA GUARDIA P. Review article:Hepatobiliary complications associated with total parenteral nutrition[J]. Aliment Pharmacol Ther, 2000, 14 (Suppl 2) :54-57.
|
|
[32] HOWARD LYN, ASHLEY C. Management of complications in patients receiving home parenteral nutrition[J]. Gastroenterology, 2003, 124 (6) :1651-1661.
|
|
[33] BESSISSOW T, l E NH, ROLLET K, et al. Incidence and predictors of nonalcoholic fatty liver disease by serum biomarkers in patients with inflammatory bowel disease[J]. Inflamm Bowel Dis, 2016, 22 (8) :1937-1944.
|
|
[34] SOURIANARAYANANE A, GARG G, SMITH TH, et al. Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease[J]. J Crohns Colitis, 2013, 7 (8) :279-285.
|
|
[35] NAGAHORI M, HYUN SB, TOTSUKA T, et al. Prevalence of metabolic syndrome is comparable between inflammatory bowel disease patients and the general population[J]. J Gastroenterol, 2010, 45 (10) :1008-1013.
|
|
[36] YORULMAZ E, ADALI G, YORULMAZ H, et al. Metabolic syndrome frequency in inflammatory bowel diseases[J]. Saudi J Gastroenterol, 2011, 17 (6) :376-382.
|
|
[37] DOLINSKY VW, DOUGLAS DN, LEHNER R, et al. Regulation of the enzymes of hepatic microsomal triacylglycerol lipolysis and re-esterification by the glucocorticoid dexamethasone[J]. Biochem J, 2004, 378 (3) :967-974.
|
|
[38] D'SOUZA AM, BEAUDRY JL, SZIGIATO AA, et al. Consumption of a high-fat diet rapidly exacerbates the development of fatty liver disease that occurs with chronically elevated glucocorticoids[J]. Am J Physiol Gastrointest Liver Physiol, 2012, 302 (8) :850-863.
|
|
[39] HUBEL JM, SCHMIDT SA, MASON RA, et al. Influence of plasma cortisol and other laboratory parameters on nonalcoholic fatty liver disease[J]. Horm Metab Res, 2015, 47 (7) :479-484.
|
|
[40] LAPUMNUAYPOL K, KANJANAHATTAKIJ N, PISARCIK D, et al. Effects of inflammatory bowel disease treatment on the risk of nonalcoholic fatty liver disease:A meta-analysis[J]. Eur J Gastroenterol Hepatol, 2018, 30 (8) :854-860.
|
|
[41] LIU TC, STAPPENBECK TS. Genetics and pathogenesis of inflammatory bowel disease[J]. Annu Rev Pathol, 2016, 11:127-148.
|
|
[42] DIGNASS A, VAN ASSCHE G, LINDSAY JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease:Current management[J]. J Crohns Colitis, 2010, 4 (1) :28-62.
|
|
[43] BATH ROOPJEET K, BRAR NAVKIRAN K, FOROUHAR FARIPOUR A, et al. A review of methotrexate-associated hepatotoxicity[J]. J Dig Dis, 2014, 15 (10) :517-524.
|
|
[44] SAKTHISWARY R, CHAN GY, KOH ET, et al. Methotrexateassociated nonalcoholic fatty liver disease with transaminitis in rheumatoid arthritis[J]. Scientific World J, 2014, 2014:823763.
|
|
[45] RUIZ AG, CASAFONT F, CRESPO J, et al. Lipopolysaccharidebinding protein plasma levels and liver TNF-alpha gene expression in obese patients:Evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis[J]. Obes Surg, 2007, 17 (10) :1374-1380.
|
|
[46] BARBUIO R, MILANSKI M, BERTOLO MB, et al. Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet[J]. J Endocrinol, 2007, 194 (3) :539-550.
|
|
[47] KOCA SS, BAHCECIOGLU IH, POYRAZOGLU OK, et al. The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine-and cholinedeficient diet[J]. Inflammation, 2008, 31 (2) :91-98.
|
|
[48] YALCIN M, AKARSU M, CELIK A, et al. A comparison of the effects of infliximab, adalimumab, and pentoxifylline on rats with non-alcoholic steatohepatitis[J]. Turk J Gastroenterol, 2014, 25 (Suppl 1) :167-175.
|
|
[49] ADAMS LA, ZEIN CO, ANGULO P, et al. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis[J]. Am J Gastroenterol, 2004, 99 (12) :2365-2368.
|
DownLoad: